(Q65318629)
Statements
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies (English)
0 references
19 February 2016
0 references
27 March 2018
0 references
114
0 references
18 year
0 references